-
Henlius' Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint
prnasia
December 08, 2021
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first interim analysis met the primary study endpoint of the overall survival (OS) of the Phase 3 clinical study (NCT04063163) of its innovative PD-1 inhibitor serplulimab...
-
Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
pharmaceutical-business-review
January 20, 2021
New option extends dosing from two to four weeks, reducing medical visits and improving patient convenience.
-
Imfinzi approved in EU to treat extensive-stage small cell lung cancer
europeanpharmaceuticalreview
September 14, 2020
Imfinzi (durvalumab) has been approved by the European Commission as a first-line treatment for extensive-stage small cell lung cancer, with chemotherapy.
-
EU approves AstraZeneca’s Imfinzi for treatment of extensive-stage small cell lung cancer
expresspharma
September 02, 2020
Imfinzi, in combination with etoposide and either carboplatin or cisplatin, is also approved in the US, Japan and several other countries for the treatment of ES-SCLC.
-
Imfinzi shows sustained OS benefit in first-line ES-SCLC in CASPIAN trial
pharmaceutical-business-review
June 03, 2020
Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin ...
-
FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer
americanpharmaceuticalreview
April 06, 2020
The Food and Drug Administration (FDA) has approved durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
-
Imfinzi’s success in ES-SCLC not matched in combo with tremelimumab
pharmaceutical-technology
March 18, 2020
AstraZeneca’s Imfinzi (durvalumab) plus standard of care (SoC) chemotherapies caused a sustained, clinically meaningful overall survival (OS) benefit in first line treatment of extensive-stage small cell lung cancer (ES-SCLC).